

The following sensitivity analyses were undertaken to explore the impact of six cycles of chemotherapy, different combinations of chemotherapy and PLAT, trials with <24 month follow-up and the one study with PEM + CARB which is not licensed in the UK.

**TABLE 97** Summary results for the direct meta-analysis and mixed-treatment comparison (HR, 95% CI) for 2-year survival for trials comparing chemotherapy vs chemotherapy in population 2: population with non-squamous disease

Reference treatment vs comparator	Direct meta-analysis 1 (n = 18), HR (95% CI)	Mixed-treatment comparison 1 (n = 18), HR (95% CI)	Mixed-treatment comparison A (n = 17), HR (95% CI)	Mixed-treatment comparison B (n = 18), HR (95% CI)	Mixed-treatment comparison C (n = 18), HR (95% CI)	Mixed-treatment comparison F (n = 18), HR (95% CI)
GEM + PLAT vs VNB + PLAT <sup>43,45,50,54,55,57</sup>	0.89 (0.66 to 1.21)	0.85 (0.63 to 1.16)	0.85 (0.63 to 1.16)	0.85 (0.63 to 1.16)	0.86 (0.65 to 1.15)	0.84 (0.65 to 1.11)
GEM + PLAT vs PAX + PLAT <sup>43,46,47,56,57,60</sup>	1.06 (0.78 to 1.46)	1.05 (0.78 to 1.44)	1.05 (0.77 to 1.44)	1.04 (0.76 to 1.42)	1.05 (0.79 to 1.42)	1.04 (0.81 to 1.36)
GEM + PLAT vs DOC + PLAT <sup>47</sup>	0.86 (0.55 to 1.34)	0.94 (0.58 to 1.47)	0.94 (0.57 to 1.49)	0.94 (0.58 to 1.49)	0.88 (0.56 to 1.36)	0.96 (0.63 to 1.40)
GEM + PLAT vs PEM + PLAT <sup>61,62</sup>	0.91 (0.33 to 2.53)	1.06 (0.59 to 1.7)	1.05 (0.58 to 1.70)	1.05 (0.58 to 1.71)	1.08 (0.61 to 1.68)	1.47 (0.87 to 2.51)
VNB + PLAT vs PAX + PLAT <sup>43,48,51,57</sup>	0.82 (0.53 to 1.28)	1.23 (0.88 to 1.72)	1.24 (0.88 to 1.73)	1.22 (0.87 to 1.71)	1.22 (0.88 to 1.69)	1.24 (0.92 to 1.66)
VNB + PLAT vs DOC + PLAT <sup>44,53,59</sup>	0.97 (0.56 to 1.68)	1.10 (0.70 to 1.65)	1.11 (0.69 to 1.68)	1.11 (0.70 to 1.68)	1.03 (0.67 to 1.52)	1.14 (0.76 to 1.6)
VNB + PLAT vs PEM + PLAT	XX	1.24 (0.63 to 2.17)	1.24 (0.62 to 2.17)	1.24 (0.63 to 2.17)	1.26 (0.65 to 2.11)	1.76 (0.95 to 3.12)
PAX + PLAT vs DOC + PLAT <sup>47</sup>	1.0 (0.79 to 1.59)	0.89 (0.53 to 1.43)	0.89 (0.53 to 1.46)	0.91 (0.54 to 1.48)	0.84 (0.52 to 1.33)	0.92 (0.58 to 1.38)
PAX + PLAT vs PEM + PLAT	XX	1.01 (0.51 to 1.76)	1.01 (0.5 to 1.76)	1.02 (0.51 to 1.79)	1.03 (0.53 to 1.73)	1.42 (0.78 to 2.53)
DOC + PLAT vs PEM + PLAT	XX	1.13 (0.54 to 2.18)	1.12 (0.53 to 2.2)	1.12 (0.53 to 2.2)	1.22 (0.59 to 2.26)	1.54 (0.81 to 3.08)

XX, no direct meta-analysis or mixed-treatment comparison undertaken.

a Direct evidence available. Direct meta-analysis A and mixed-treatment comparison A: sensitivity analysis excluding Chen *et al.*<sup>52</sup> (<24 months follow-up time) and Tan *et al.*<sup>59</sup> (used six cycles of chemotherapy). Direct meta-analysis B and mixed-treatment comparison B: sensitivity analysis using data from PAX + CIS instead of PAX + CARB from the Schiller *et al.* trial.<sup>47</sup> Direct meta-analysis C and mixed-treatment comparison C: sensitivity analysis using data from DOC + CARB instead of DOC + CIS from the Fossella *et al.* trial.<sup>44</sup> Direct meta-analysis D and mixed-treatment comparison D: sensitivity analysis excluding Tan *et al.*<sup>59</sup> (used six cycles of chemotherapy). Direct meta-analysis E and mixed-treatment comparison E: sensitivity analysis excluding Chen *et al.*<sup>52</sup> (<24 months follow-up time). Direct meta-analysis F and mixed-treatment comparison F: sensitivity analysis excluding Gronberg *et al.*<sup>62</sup> (contains PEM + CARB which is not licensed in the UK).

A HR > 1 favours the reference treatment and a HR < 1 favours the comparator treatment.